Sernova Corp V.SVA

Primary Symbol: T.SVA Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.

TSX:SVA - Post by User

Sernova Corp

Bullboard Posts

Post by jwalliscaon Mar 20, 2020 12:10pm

445 Views

Post# 30830773

31 Jan 2020 Financials & MD&A in SEDAR! AGM 30 April :)

Excerpt from MD&A (notice "plural" in use):
Subjects continue to be enrolled, implanted with the Cell Pouch and transplanted with islets in this trial at the University of Chicago clinical site.
... continued...
We are also developing collaborations with pharmaceutical companies and evaluating their proprietary sources of glucose-responsive stem cell-derived cell technologies in combination with our Cell Pouch technologies with the goal to establish potential longterm licensing and co-development relationships. Regarding our platform technologies, the Company continuesto investigate other diseases amenable to treatment with therapeutic cells within the Cell Pouch where proteins, hormones or other factors are required to treat disease.
... continued...

Under Research and Development (application to broader diabetic community):
Advancing a treatment that we believe could benefit the broader diabetes population consisting of the Cell Pouch transplanted with locally immune protected glucose-responsive stem cell-derived cells using our licensed technology; and ... continued...


Sernova Corp.	Mar 19 2020	21:11:55 ET	52-109FV2 - Certification of interim filings - CEO (E)	PDF	181 K
Sernova Corp.	Mar 19 2020	21:11:55 ET	52-109FV2 - Certification of interim filings - CFO (E)	PDF	208 K
Sernova Corp.	Mar 19 2020	21:08:33 ET	Interim financial statements/report - English	PDF	347 K
Sernova Corp.	Mar 19 2020	21:10:03 ET	MD&A - English	PDF	572 K
Sernova Corp.	Feb 20 2020	12:38:44 ET	Notice of the meeting and record date - English	PDF	116 K